Stockreport

BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease [Yahoo! Finance]

BioRestorative Therapies, Inc.  (BRTX) 
NASDAQ:AMEX Investor Relations: biorestorative.com/content/investor-relations
PDF No adverse events related to dose-limiting toxicities associated with hypoxic-cultured mesenchymal stem cells Presented at the 2026 Orthopaedic Research Society Annua [Read more]